Navigation Links
Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
Date:9/12/2012

MOUNTAIN VIEW, Calif., Sept. 13, 2012 /PRNewswire/ -- Edison Pharmaceuticals today announced positive results of a recently completed phase 2A study entitled, "Prospective Open Label Study of EPI-743 in Children with Leigh Syndrome (Subacute Necrotizing Encephalomyelopathy)." The study was conducted at the Ospedale Pediatrico Bambino Gesu– the Vatican's children's hospital, Rome, Italy.

Ten children with seven differing subtypes of Leigh syndrome, ranging in age from 1-13 years, were treated with EPI-743. All ten children exhibited reversal of disease progression as measured by four different disease-relevant metrics. The clinical response was durable over 180 days. No significant safety events were observed.

The results of the clinical trial were published on-line September 10, 2012 in the journal Molecular Genetics and Metabolism.

Findings obtained in this prospective phase 2 controlled study confirm previous clinical results obtained in the United States and Europe.

Leigh syndrome is an inherited lethal, progressive, predominately pediatric, neuromuscular disorder for which there are no approved treatments. Initially described in 1951, the hallmarks of the disease include bilateral necrosis (death) of central nervous system regions responsible for the control of breathing and other neurologic functions. Leigh syndrome belongs to a large family of disorders identified as "mitochondrial disease." The disorders share as a common biochemical feature defects in cellular energy metabolism.

EPI-743 is an orally bioavailable small molecule being developed by Edison Pharmaceuticals for the treatment of Leigh syndrome and other inherited mitochondrial diseases. EPI-743 is a member of the para-benzoquinone class of drugs. It serves as a cofactor for the novel drug target– NADPH quinone oxidase 1 (NQO1). Through a redox-based mechanism, EPI-743 augments endogenous glutathione biosynthesis– essential for the control of oxidative stress.

Results obtained in this trial represent the first published report of disease reversal in an otherwise progressive and fatal neurological disease.

Edison Pharmaceuticals

Edison Pharmaceuticals is a specialty pharmaceutical company dedicated to developing treatments for children with orphan mitochondrial diseases.


'/>"/>
SOURCE Edison Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
2. Carolinas HealthCare System and Edison Nation Collaborate to Drive Medical Innovation and Technology
3. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
6. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
7. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
8. Icahn Issues Statement Regarding Amylin Pharmaceuticals
9. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
10. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
11. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Jan. 20, 2017  Ethicon Endo-Surgery, Inc. ... Medical Products, Inc., a privately held medical ... electrosurgical tools used in operating rooms worldwide. ... Ethicon,s* advanced energy devices with Megadyne,s innovative ... step forward in Ethicon,s goal to deliver ...
(Date:1/20/2017)... 2017 Entscheidung fällt ... Die internationale humanitäre Stadt soll um knapp ... Seine Hoheit Scheich Muhammad bin ... Herrscher von Dubai , hat den ... (International Humanitarian City IHC) zu verdreifachen, um den Betrieb ...
(Date:1/19/2017)... , Jan. 19, 2017 The Global ... understanding and access to partnering deals and agreements entered ... Trends in partnering deals - Top deals by value ... of development, technology type The report provides understanding ... into by the world,s leading healthcare companies. The ...
Breaking Medicine Technology:
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... "ProDOF is the perfect set of tools ... to another subject in a scene," said Christina Austin - CEO of Pixel Film Studios. ... scene. Easily create the illusion of a DSLR racking focus from one area into ...
(Date:1/21/2017)... ... January 21, 2017 , ... Northern California Medical ... recently joined their multi-specialty medical group. The dermatology practice provides general dermatologic treatment, ... excited to add this excellent dermatology practice to our group’s medical services,” explains ...
(Date:1/20/2017)... ... ... Launches New ADA Portable Motion Trek BP 300 Lift. Built for durability, this pool lift ... can be wheeled out of the way and stored when not in use. It is ... the feedback from customers into specific enhancements and created a new product that is built ...
(Date:1/20/2017)... ... January 20, 2017 , ... Doctor C LLC, a company based out of ... show to continue the marketing and distribution of its product, The Right C. , ... percent better absorption than traditional vitamin C supplements. At the trade show, Doctor C ...
(Date:1/20/2017)... ... , ... International Protein, a company based out of Australia that focuses on ... ECRM trade show in Hilton Head, SC. , International Protein was founded by ... line of products that would elevate her fitness regime. At this ECRM trade show, ...
Breaking Medicine News(10 mins):